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ABSTRACT
Objectives: To examine the cross-sectional
association between serum perfluorooctanate (PFOA),
perfuorooctane sulfonate (PFOS), perfluorononanoic
acid (PFNA) and perfluorohexane sulfonate (PFHxS)
concentrations with self-reported memory impairment
in adults and the interaction of these associations with
diabetes status.
Design: Cross-sectional study.
Setting: Population-based in Mid-Ohio Valley, West
Virginia following contamination by a chemical plant.
Participants: The C8 Health Project collected data
and measured the serum level of perfluoroalkyl acids
(PFAAs) of 21 024 adults aged 50+ years.
Primary outcome measure: Self-reported memory
impairment as defined by the question ‘have
experienced short-term memory loss?’
Results: A total of 4057 participants self-reported
short-term memory impairment. Inverse associations
between PFOS and PFOA and memory impairment
were highly statistically significant with fully adjusted
OR=0.93 (95% CI 0.90 to 0.96) for doubling PFOS
and OR=0.96 (95% CI 0.94 to 0.98) for doubling PFOA
concentrations. Comparable inverse associations with
PFNA and PFHxS were of borderline statistical
significance. Inverse associations of PFAAs with
memory impairment were weaker or non-existent in
patients with diabetes than overall in patients without
diabetes.
Conclusions: An inverse association between PFAA
serum levels and self-reported memory impairment has
been observed in this large population-based, cross-
sectional study that is stronger and more statistically
significant for PFOA and PFOS. The associations can
be potentially explained by a preventive anti-
inflammatory effect exerted by a peroxisome
proliferator-activated receptor agonist effect of these
PFAAs, but confounding or even reverse causation
cannot be excluded as an alternative explanation.
INTRODUCTION
Perﬂuoroalkyl acids (PFAAs) are man-made
compounds used during the manufacture of
ﬂuoropolymers including non-stick cookware
and breathable, yet waterproof, fabrics.
They can also result from the metabolism of
ﬂuorinated telomers, compounds used
for food package coatings, carpet treatments
and stain-resistant fabric treatment.
Perﬂuorooctanate (PFOA), perfuorooctane
ARTICLE SUMMARY
Article focus
▪ Cross-sectional association between the serum
level of perfluorooctanate (PFOA), perfluoro-octane
sulfonate (PFOS), perfluorononanoic acid (PFNA)
and perfluorohexane sulfonate (PFHxS) and self-
reported memory impairment in a population
exposed to high levels of PFOA.
▪ Potential interaction between the association of
perfluoroalkyl acids (PFAAs) with memory
impairment by diabetes status.
Key messages
▪ Inverse associations between PFOS and PFOA
and memory impairment were statistically signifi-
cant, perhaps due to a potential anti-
inflammatory effect exerted through a peroxi-
some proliferator-activated receptor agonism.
Comparable inverse associations with PFNA and
PFHxS were of borderline statistical significance.
▪ Inverse associations of PFAAs with memory
impairment were weaker or non-existent in
patients with diabetes than overall in patients
without diabetes. Analysis further stratified by
specific diabetes medication use showed no vari-
ation in ORs more than explicable by chance
given the number of tests made.
Strengths and limitations of this study
▪ Very large sample size including 21 024 adults
with a measured serum level of PFAAs with a
given geographical distribution allowing some
multilevel modelling.
▪ The cross-sectional nature of the design does
not allow any causal inference and makes results
particularly prone to reverse causality.
▪ A self-report is not an optimal method for
estimating the degree of memory impairment in
a population.
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sulfonate (PFOS), perﬂuorononanoic acid (PFNA) and
perﬂuorohexane sulfonate (PFHxS) persist in the envir-
onment and are found in the blood of humans and
many animal species throughout the world.1 2 Potential
sources of exposure to PFAAs in humans include drink-
ing water, dust, breast milk, ﬁsh and other foods, food
packaging, ambient air, and occupational exposure.3–6
In animal models, perﬂuoroalkyl chemicals can acti-
vate peroxisome proliferator-activated receptor α
(PPARα), a ligand-activated transcription factor that reg-
ulates gene expression, lipid modulation, glucose
homeostasis, cell proliferation and inﬂammation.7 8 The
PPAR receptor has been involved in the ageing process:
PPARα null mice showed decreased longevity compared
with wild-type mice due to non-neoplastic spontaneous
ageing lesions which occurred with a higher incidence
and a shorter latency in the PPARα null mice.9 Also,
PPARγ variants were reported to be associated with lon-
gevity in humans with low-insulin resistance.10 11
Activation of the PPARγ receptor in vitro and in vivo
also prevents the expression of inﬂammatory cytokines
and other inﬂammatory mediators in brains of
Alzheimer’s disease animal models.12 13 In addition,
PPARγ agonists have been demonstrated to suppress the
Aβ-mediated activation of microglia in vitro and prevent
cortical or hippocampal neuronal cell death.14–16 PPARγ
is also deeply involved in diabetes, given its ability to
orchestrate the expression of genes involved in lipid
metabolism, adipogenesis and inﬂammation. It is acti-
vated by endogenous ligands (such as fatty acids and
prostaglandins) or drugs such as thiazolidinedione. It is
most highly expressed in adipocytes where it acts as the
master regulator of adipogenesis via induction of adipo-
genic genes.17 However, a study in vitro showed that
PFOA and PFOS activate differentially PPARα and
PPARγ receptors, but it is not possible to directly
extrapolate these results to toxicity studies in vivo.18
Therefore, in line with what was recently observed by
Power et al,19 we hypothesised that increased exposure to
PFAA could be associated with a better cognitive
function.
The positive association between diabetes and cogni-
tive impairment is well established20; some studies inves-
tigating the association between PFOA exposure and
diabetes suggested the presence of an inverse associ-
ation: a negative trend in diabetes occurrence by
increasing serum PFOA deciles was found in a case–
control study nested in a previous study based on the
population investigated here,21 22 but not in others.23 24
From 1950 to 2005, a chemical plant in the Mid-Ohio
Valley, West Virginia was responsible for emitting PFOA
into the surrounding environment. In 2001, a group of
residents from the nearby West Virginia and Ohio com-
munities ﬁled a class action lawsuit alleging health
damage from drinking water supplies drawing on
PFOA-contaminated groundwater.25 Part of the pretrial
settlement of the class action lawsuit included a baseline
survey, the C8 Health Project, conducted in 2005–2006,
that gathered data from over 69 000 people from six
contaminated water districts surrounding the plant.25 In
the present population, PFOA concentrations ranged
from US background levels to very high; overall, the
PFOA levels are much higher in this population (geo-
metric mean 42.6 ng/ml, 95% CI 41.8 to 43.3) than in
the corresponding US population surveys (NHANES in
same year mean 3.95 ng/ml, 95% CI 3.65 to 4.27).1 25
The mean PFOS (geometric mean 22.4, 95% CI 22.2 to
22.6), PFNA (1.37, 95% CI 1.36 to 1.38) and PFHXs
(3.18, 95% CI 3.15 to 3.22) closely resembled values
from a nationally representative US sample from a
similar time frame (mean PFOS 20.7, 95% CI 19.2 to
22.3; mean PFNA 0.97, 95% CI 0.82 to 1.14 and PFHXs
1.93, 95% CI 1.73 to 2.16).1
The present study uses these data to examine the
cross-sectional association between serum PFOA, PFOS,
PFNA and PFHxS concentrations with self-reported
memory impairment in adults, and its potential inter-
action with diabetes status.
METHODS
Study population
This study is one of the C8 Science Panel Studies that
uses information from questionnaires and blood tests
collected in the C8 Health Project, supplemented by
further information on classiﬁcation by water district
developed in a companion C8 Science Panel Study.
The C8 Health Project enrolled eligible participants
between August 2005 and August 2006. Individuals were
eligible to participate in the C8 Health Project if they
had consumed water for at least 1 year between 1950
and 3 December 2004 while living, working or going to
school in one of the following six water districts: Little
Hocking Water Association of Ohio; City of Belpre,
Ohio; Tupper Plains-Chester District of Ohio; Village of
Pomeroy, Ohio; Lubeck Public Service District of West
Virginia; Mason County Public Service District of West
Virginia or private water sources within aforementioned
districts and areas of documented PFOA contamination.
Details of the study enrolment process, including con-
senting procedures, have been described elsewhere.25
The C8 Health Project collected data on 69 030
people. The participation rate for the C8 Health Project,
based on US census counts of residents in the affected
water districts during Project enrolment, has been esti-
mated at around 80%.25 In this population, the strongest
predictor of PFOA serum concentration was residence in
one of the contaminated water districts26; the serum
levels of other PFAAs do not show such geographic vari-
ation. Of the population, 21 724 older adults (aged
≥50 years) were considered for this analysis, and a total
of 21 024 (96.8%) were included in the ﬁnal analysis
after exclusion of participants with missing data on eth-
nicity, education level, socioeconomic status, cigarette
smoking or body mass index (BMI) measurements.
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Memory impairment definition
During the survey (2005–2006), all participants were
asked if they ‘had experienced short-term memory loss’,
the possible answers being ‘frequently’, ‘sometimes’,
‘rarely’ and ‘never’. The principle analyses assessed
memory impairment deﬁned as reporting short-term
memory loss frequently or sometimes, compared with
rarely and never. Memory impairment ever was also con-
sidered, deﬁned as reporting any memory loss and com-
pared with the never category.
Laboratory analysis
Blood samples were obtained and processed at individ-
ual data collection sites. Samples were drawn into four
tubes/participant, with a maximum 35 ml. Tubes were
spun, aliquoted and refrigerated until shipping. Samples
were shipped on dry ice daily from each data collection
site to the laboratory daily.25 Participants were not asked
to fast before blood sample withdrawal, but fasting status
was recorded.
Laboratory analysis of PFAAs used an automated solid-
phase extraction combined with reverse-phase high-
performance liquid chromatography.27 Analyses were
conducted by the Exygen Research Inc, State College,
Pennsylvania, USA; an intralaboratory quality assurance
programme was carried out by analysis of duplicate
samples at AXYS Analytical Service Ltd, Sidney, British
Columbia, Canada.25 The intralaboratory coefﬁcient of
variation for all PFAAs measurements was 0.1; the inter-
laboratory comparison coefﬁcient of variation was 0.2
for PFOA and PFNA, 0.1 for PFOS and not applicable
for PFHxA as all in the second lab measurement values
were below the level of detection.25 The detection limit
for all PFAAS was 0.5 ng/ml and observations below this
limit were assigned a value of 0.25 ng/ml (n=16, n=101,
532 and 387 for PFOA, PFOS, PFNA and PFHxS,
respectively, for this study population). All PFAAs con-
centration distributions were skewed to the right.
Methods and results are reported according to the
STROBE-ME recommendations.28
Statistical analysis
Associations between exposure (serum concentrations of
PFOA, PFOS, PFNA and PFHxS) and memory impairment
were studied using logistic regression. Minimally adjusted
models included age, in 1-year age-band, race (white,
black and others), gender and educational level (high-
school diploma or general educational development,
some college, bachelor’s degree or higher; model 1).
Further adjusted models additionally included average
household income (≤$10 000, $10 001–20 000, $20 001–
30 000, $30 001–40 000, $40 001–50 000, $50 001–60 000,
$60 001–70 000, >$70 000), physical activity, alcohol con-
sumption (none, <1 drink/month, <1 drink/week, few
drinks/week, >1 drink/day) and cigarette smoking (never
smoker, former smoker, current smoker <10 cigarettes/
day, current smoker 10–19 cigarettes/day, current smoker
≥20 cigarettes/day; model 2). Fully adjusted models also
included BMI (underweight/normal weight; overweight
and obese class I, II and III) and diabetes (model 3).
PFAA concentrations were log-transformed to reduce skew-
ness. For each model, the association between PFAAs and
self-reported memory impairment was calculated for a
doubling in PFAA concentration in a model with PFAA
entered as a continuous covariate, for quintile groups of
the PFAA distribution and by ordinal regression analysis
with the outcome variable comprising the four original
levels of self-reported frequency of episodes of memory
loss, again in relation to a doubling of PFAAs. To explore
the possible differential effects of PFAA in subgroups, ana-
lyses were further stratiﬁed by diabetes status and, among
patients with diabetes, by type of medications.
The following four sensitivity analyses were carried
out: ﬁrst, one analysis restricting the sample to 7097 par-
ticipants aged 65 years and older. Second, an analysis
conducted on the entire sample, but using as outcome
deﬁnition those reporting any memory loss (frequently,
sometimes and rarely). Our ﬁnal sensitivity analysis uti-
lises the geographical clustering of PFOA exposure by
water districts which allowed use to decompose the
overall estimate of association of PFOA with memory
impairment within and between water district compo-
nents, by including as explanatory variables both water
district mean logged PFOA serum concentration and
the deviations of individual values from their district
mean.29 These two associations are subject to different
potential biases, thus helping interpretation.
Role of funding
Funding for this work, the ‘C8 Science Panel
Community Study at London School of Hygiene and
Tropical Medicine—LSHTM’, comes from the C8 Class
Action Settlement Agreement (Circuit Court of Wood
County, West Virginia, USA) between DuPont and the
plaintiffs, which resulted from releases of PFOA (or C8)
into drinking water. It is one of the C8 Science Panel
Studies undertaken by the Court-approved C8 Science
Panel established under the same Settlement
Agreement. The task of the C8 Science Panel, of which
Tony Fletcher is a member, is to undertake research in
the Mid-Ohio Valley, and subsequently evaluate the
results along with other available information to deter-
mine if there are any probable links between PFOA and
disease. Funds were administered by the Garden City
Group (Melville, New York, USA) that reports to the
Court. The authors of this manuscript declare that their
ability to design, conduct, interpret or publish research
was unimpeded by and fully independent of the court
and/or settling parties. In addition, they declare no
competing ﬁnancial interests. The LSHTM Ethics
Committee approved this study.
RESULTS
A total of 4462 participants (21.2% of the entire popula-
tion of 21 024 individuals aged 50 years or older) self-
Gallo V, Leonardi G, Brayne C, et al. BMJ Open 2013;3:e002414. doi:10.1136/bmjopen-2012-002414 3
Perfluoroalkyl acids and memory impairment
reported short-term memory impairment (ﬁgure 1): epi-
sodes of short-term memory loss were reported fre-
quently by 1115 participants (5.3%); sometimes by 3347
(15.9%); rarely by 4283 (20.4%) and never by 12 279
(58.4%). Many personal characteristics were associated
individually with memory loss, including higher age,
lower socioeconomic status, smoking and diagnosis of
diabetes (table 1), though to what extent these reﬂected
independent risk factors was not investigated.
Results from the logistic regression of association
between PFAAs and memory impairment are shown in
table 2. Results for the minimally, further and fully
adjusted models were similar, so we show only the
further adjusted results in this table, but results for all
models are in the online supplementary table S1.
Inverse associations between PFOS and PFOA and
memory impairment were highly statistically signiﬁcant
with adjusted OR=0.93 (0.90 to 0.96) for PFOS and
OR=0.96 (0.94 to 0.98) for PFOA for doubling PFAA
concentrations. Inverse associations of similar magnitude
with PFNA and PFHxS but of borderline statistical sig-
niﬁcance were found: OR=0.96 (0.92 to 1.02) for PFNA
and OR=0.97 (0.94 to 1.00) for PFHxS. The analysis by
the PFAA quintile groups shows similar patterns.
Inverse associations of PFAAs with memory impair-
ment were weaker or non-existent in patients with dia-
betes than in patients without diabetes (table 3), though
ORs were imprecise, and the difference by diabetes
status was only signiﬁcant for PFOA (p value for inter-
action = 0.014). Analysis further stratiﬁed by speciﬁc dia-
betes medication use showed no variation in ORs more
than explicable by chance given the number of tests
made (see online supplementary table S2).
In the sensitivity analysis on participants older than
65 years, the substantial reduction of the sample size
resulted in loss of precision in ORs. However, the points
estimates of associations with memory impairment were
of comparable magnitude for all PFAAs except PFOA for
which the association with memory impairment was
close to null (OR=0.99 (0.97 to 1.03); table 4).
The analysis carried out on the entire sample, compar-
ing those with any memory impairment against those
with no memory problems, shows slightly weaker associa-
tions for each of the PFAAs but precision was reduced
(table 4). Analyses using ordinal regression in place of
binary logistic regression yielded similar results to the
logistic regressions (tables 2–4).
The analysis separating the PFOA-memory impairment
association within and between water district compo-
nents found that within water districts there was an
inverse association between PFOA and memory impair-
ment, as in the overall association (OR 0.94, 95% CI
0.91 to 0.98, scale and adjustments as before). However,
there was no association between geometric mean con-
centration and memory impairment (OR 1.00, 95% CI
0.97 to 1.03, per doubling in geometric mean PFOA by
district).
DISCUSSION
An inverse association between PFAAs serum levels
(including PFOS, PFOA, PNA and PFHxS) and self-
reported memory impairment has been observed in this
large population-based, cross-sectional study. This associ-
ation is more clearly monotonic with increasing expos-
ure, and more statistically signiﬁcant for PFOA and
PFOS. However, the consistent decrement for all PFAAs
suggests a common mechanism.
It is plausible that PFAAs could have an effect on cog-
nitive function via PPAR agonism. Although it is not
clear to what extent PFAAs act differentially on the
PPAR receptors α and γ,18 it could be speculated that
this association might be mediated by the activation of
the PPAR receptor by PFAAs. Activation of the PPARγ
receptors has been shown to decrease the secretion of
proinﬂamatory cytokines and possibly increase phagocyt-
osis of Aβ inclusions, probably through the activation of
microglia.30 However, there was a suggestion that this
effect of suppression of the activation of microglia was
age-dependent or disease stage-dependent, being not
signiﬁcant in patients with advanced Alzheimer’s
disease.31 32 PPAR agonist drugs, such as non-steroidal
anti-inﬂammatory drugs and some antidiabetic drugs
(ie, thiazolidinedione or pioglitazone), have been pro-
posed as preventive drugs for neurodegenerative condi-
tions, including Alzheimer’s dementia.30 33
In a previous published study, an inverse association
between PFAAs and memory impairment was observed
speciﬁcally among non-medicated patients with dia-
betes.19 In the present study, this pattern was not repli-
cated, with the inverse association between PFAAs and
cognitive impairment being more evident in those
without diabetes; among patients with diabetes, the asso-
ciation was not present, irrespective of treatment status.
This ﬁnding could be explained by the fact that in
patients with diabetes, PPAR receptors are more
Figure 1 Prevalence of self-reported short-term memory
impairment by age and sex in the study population.
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Table 1 Participant characteristics, Mid-Ohio Valley, 2005–2006 (N=21 024)
All N=21024* Memory impaired N=4462†
Males, n (%) 10353 (49.2) 2040 (19.7)
Females, n (%) 10671 (50.8) 2422 (22.7)
Age, median/mean (SD) 60.5/62.3 (9.0) 59.9/62.3 (9.4)
Age groups (year)
50–54 5381 (25.6) 1185 (22.0)
55–59 4831 (23.0) 1055 (21.8)
60–64 3715 (17.7) 740 (19.9)
65–69 2930 (13.9) 535 (18.3)
70–74 1979 (9.4) 419 (21.2)
75–79 1251 (6.0) 269 (21.5)
80+ years 937 (4.5) 259 (27.6)
Regular exercise, n (%) 6774 (32.2) 1306 (19.3)
BMI, n (%)
Normal weight 5100 (24.3) 1051 (20.6)
Overweight 8194 (39.0) 1612 (19.7)
Obese class I 4789 (22.8) 1028 (21.5)
Obese class II 1805 (8.6) 457 (25.3)
Obese class III 1136 (5.4) 314 (27.6)
Household income, $/year n (%)
≤10 000 1486 (7.1) 448 (30.2)
10 001–20 000 3059 (14.6) 757 (24.8)
20 001–30 000 3281 (15.6) 751 (22.9)
30 001–40 000 2936 (14.0) 572 (19.5)
40 001–50 000 2135 (10.2) 422 (19.8)
50 001–60 000 1815 (8.6) 359 (19.8)
60 001–70 000 1367 (6.5) 268 (19.6)
>70 000 2882 (13.7) 480 (16.7)
Undetermined 2063 (9.8) 405 (19.6)
Education, n (%)
<12 years 3310 (15.7) 845 (25.5)
HS diploma or GED 9704 (46.2) 1979 (20.4)
Some college 5612 (26.7) 1204 (21.5)
Bachelor degree or higher 2398 (11.4) 434 (18.1)
Race, n (%)
White 20514 (97.6) 4349 (21.2)
Black 213 (1.0) 38 (17.8)
Other 297 (1.4) 75 (25.3)
Alcohol consumption, n (%)
None 13276 (63.2) 2848 (21.5)
<1 drink/month 2589 (12.3) 597 (23.1)
<1 drink/week 1530 (7.3) 309 (20.2)
Few drinks/week 2087 (9.9) 397 (19.0)
1–3 drinks/day 805 (3.8) 142 (17.6)
>3 drinks/day 310 (1.5) 66 (21.3)
Undetermined 427 (2.0) 103 (24.1)
Smoking status, n (%)
Never smoker 9804 (46.6) 1906 (19.4)
Former smoker 7555 (35.8) 1693 (22.5)
Current smoker <10 cigarette/day 1212 (5.8) 256 (21.1)
Current smoker 10–19 cigarette/day 1260 (6.0) 310 (24.6)
Current smoker 20+ cigarette/day 1213 (5.8) 297 (24.5)
Diabetes, n (%) 3443 (16.4) 875 (25.4)
Thiazolidinedion use∼ 809 (23.5) 202 (25.0)
Other medications∼ 1244 (36.1) 321 (25.8)
No medication∼ 1390 (40.4) 352 (25.3)
*Percentages refer to the proportion with respect to the entire population.
†Percentages reflect the proportion of memory impaired in each category; percentages among patients with diabetes only.
BMI, body mass index; GED, general educational development.
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phosphorylated with a consequent reduced transcrip-
tional activity,34 35 and the balance between PPARγ
expression and activity levels is altered.34 36 It is therefore
possible—based on the present data—that the
PPAR-agonist effect of PFAAs is different in participants
with and without PPAR-mediated metabolic changes such
as diabetes. Also, it has been reported that PFAAs have a
PPAR agonist effect, more prominently PPAR-α37; animal
models suggest that PFOA has a stronger agonistic effect
than PFOS.37 Our ﬁndings of an inverse association
between PFAA and memory impairment among patients
without diabetes would therefore be compatible with a
possible anti-inﬂammatory role exerted by PFAA on early
symptoms of cognitive impairment.
There is some evidence of detrimental effects of
PFAAs in the neurodevelopment of mice affecting the
cholinergic system and cognitive function38–40; thus, the
timing of exposure may also be relevant in order for the
PFAAs to exert this hypothesised antidementing role.
However, these ﬁndings should be interpreted cau-
tiously, given the limitations of the study. First, given the
cross-sectional nature of the study, reverse causality must
be considered: participants suffering from memory
impairment could have consumed less of these com-
pounds via water and food sources, though this is not a
likely explanation, given the consistency of the associ-
ation across various PFAAs which have substantially dif-
ferent routes of exposure. Host characteristics such as
genotype could be correlated with both some mechan-
ism predisposing these symptoms and variation in the
PFAA excretion rates, thus leading to a confounded asso-
ciation with the serum levels. Further, a self-report is not
a very accurate method for ascertaining memory impair-
ment, although errors in classiﬁcation would be
expected to be non-differential misclassiﬁcation, biasing
the estimate of association towards the null. The effects
of PFAA have been mostly studied in relation to PPARα,7
while the receptor is mostly implicated in metabolic
changes and diabetes and in dementia PPARγ30;
however, these two belong to the same receptor family
and some degree of cross-activation cannot be excluded,
and the knowledge of their pleiotropic effects is cur-
rently advancing.41 Lastly, the classiﬁcation into different
antidiabetic medications is uncertain as these were self-
reported and not prompted by interviewers. However,
we consider it very unlikely that any misreporting would
be confounded with serum PFAAs. This would tend to
low speciﬁcity and thus bias of the association (if any)
towards the null.
On the other hand, the strengths of this study include
the fact that all the estimates shown were adjusted for
numerous potential confounders, including age in
1-year age bands, making the effect of PFAA on memory
impairment not likely to be confounded by lifestyle char-
acteristics. Furthermore, these results are based on a
very large population representative of the general
population in West Virginia and Ohio25; thus, the esti-
mates are solid; and the 21% prevalence of memory
impairment is compatible and consistent with the
ﬁgures on the prevalence of dementia reported for
North America.42
Individual serum levels reﬂect the contributions of
both the intake and retention/excretion rates. While we
have no direct data on either of these components, the
large differences in drinking water contamination and
associated average population serum levels for PFOA in
the six water districts allow an estimate of the effect of
exposure. That the association with PFOA was entirely
within the water districts, and not present at all between
water districts despite the large differences in
Table 2 Association between PFAAs and self-report
memory impairment in logistic regression for a doubling
PFAA concentration, by quintiles of PFAAs and in ordinal
regression (n=21 024)
Range
(ng/ml)
Adjusted OR and
95% CI*
PFOS 0.93 (0.90 to 0.96)
1st quintile 0.25–14.4 Ref.
2nd quintile 14.5–20.4 0.96 (0.87 to 1.07)
3rd quintile 20.5–27.1 0.86 (0.78 to 0.96)
4th quintile 27.2–37.2 0.87 (0.78 to 0.96)
5th quintile 37.3–759.2 0.85 (0.76 to 0.94)
Trend <0.001
Ordinal regression 0.95 (0.93 to 0.98)
PFOA 0.96 (0.94 to 0.98)
1st quintile 0.25–14.0 Ref.
2nd quintile 14.1–27.0 0.88 (0.79 to 0.97)
3rd quintile 27.1–53.8 0.83 (0.75 to 0.92)
4th quintile 53.9–118.1 0.79 (0.71 to 0.88)
5th quintile 118.3–22412 0.79 (0.71–0.88)
Trend <0.001
Ordinal regression 0.97 (0.96 to 0.98)
PFNA 0.96 (0.91 to 1.00)
1st quintile 0.25–0.90 Ref.
2nd quintile 1.0–1.2 0.86 (0.78 to 0.96)
3rd quintile 1.3–1.4 0.87 (0.77 to 0.98)
4th quintile 1.5–1.9 0.86 (0.77 to 0.95)
5th quintile 2.0–28.6 0.89 (0.80 to 0.99)
Trend 0.053
Ordinal regression 0.97 (0.94–1.01)
PFHxS 0.96 (0.93–0.99)
1st quintile 0.25–1.7 Ref.
2nd quintile 1.8–2.6 1.01 (0.91–1.12)
3rd quintile 2.7–3.6 1.02 (0.91–1.13)
4th quintile 3.7–5.6 0.93 (0.84–1.04)
5th quintile 5.7–232.6 0.89(0.79–0.99)
Trend 0.009
Ordinal regression 0.97 (0.94–0.99)
*Model adjusted for age (1-year age bands), ethnicity, gender and
school level (categorical), household income (categorical),
physical activity, alcohol consumption (categorical, none/<1 drink/
month, <1 drink/week, few drinks/week, 1–3 drinks/day, >3 drinks/
day, undetermined) and cigarette smoking (categorical, never,
former, <10 cigarette/day, 12–20 cigarette/day, 20+ cigarette/day).
PFAA, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate;
PFNA, perfluorononanoic acid; PFOA, perfluorooctanate; PFOS,
perfuorooctane sulfonate.
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(geometric) mean PFOA between districts (range 15.7–
405.1), is suggestive of a bias operating at one or both of
these levels. The between-district estimate is not vulner-
able to reverse causation or confounding at the individ-
ual level, though some ecological confounding may
operate if it happens to correlate with the exposure
level. Conversely, the within-district estimate but not
between-district estimate could reﬂect such individual
confounding if present. Thus, either the association
documented at the individual level could be con-
founded (eg, by some unmeasured individual character-
istic), or the association at the district level is
confounded to obscure association (eg, socioeconomic
status). This sensitivity analysis cannot prove the
Table 3 Association between PFAAs and self-report memory impairment in logistic regression for a doubling PFAA
concentration, by quintiles of distribution and in ordinal regression by diabetes status (validated by clinical records)
Range
(ng/ml) N
PFOS
N=17832 OR (95% CI)*
p Value
for inter
PFOA
N=17832 OR (95% CI)*
p Value
for inter
Patients without
diabetes
0.93 (0.90 to 0.96)† – 0.95 (0.93 to 0.97)† –
Ordinal regression 0.96 (0.93 to 0.99) 0.96 (0.95 to 0.98)
1st quintile 0.25–14.5 Ref. 0.25–14.3 Ref.
2nd quintile 14.6–20.5 0.96 (0.86 to 1.08) 14.4–27.2 0.85 (0.76 to 0.95)
3rd quintile 20.6–27.0 0.90 (0.80 to 1.01) 27.3–54.3 0.82 (0.73 to 0.92)
4th quintile 27.1–37.1 0.88 (0.78 to 0.99) 54.4–119.1 0.76 (0.68 to 0.86)
5th quintile 37.2–759.2 0.85 (0.76 to 0.96) 119.2–8416 0.75 (0.67 to 0.84)
Trend 0.002 <0.001
N=3192 N=3192
Patients with
diabetes
0.94 (0.88 to 1.02)† 0.698 1.02 (0.97 to 1.06)† 0.014
Ordinal regression 0.95 (0.90 to 1.01) 1.00 (0.97 to 1.04)
1st quintile 0.25–13.6 Ref. 0.25–12.6 Ref.
2nd quintile 13.7–20.0 1.06 (0.82 to 1.36) 12.7–25.4 1.04 (0.80 to 1.34)
3rd quintile 20.1–27.3 0.82 (0.63 to 1.06) 25.5–48.0 0.88 (0.67 to 1.14)
4th quintile 27.4–37.3 0.87 (0.67 to 1.13) 48.1–102.1 1.04 (0.80 to 1.35)
5th quintile 37.4–272.0 0.90 (0.69 to 1.17) 102.4–
22,412
1.09 (0.84 to 1.42)
Trend 0.162 0.543
PFNA PFHxS
N=17 832 N=17 832
Patients without
diabetes
0.95 (0.90 to 0.99)† – 0.96 (0.93 to 0.99)† –
Ordinal regression 0.97 (0.93 to 1.01) 0.97 0.94 to 0.99)
1st quintile 0.25–0.9 Ref. 0.25–1.8 Ref.
2nd quintile 1.0–1.2 0.86 (0.77 to 0.97) 1.9–2.6 0.98 (0.87 to 1.10)
3rd quintile 1.3–1.5 0.85 (0.76 to 0.95) 2.7–3.7 0.99 (0.89 to 1.11)
4th quintile 1.6–1.9 0.83 (0.73 to 0.93) 3.8–5.7 0.93 (0.82 to 1.05)
5th quintile 2.0–28.6 0.88 (0.78 to 0.99) 5.8–232.6 0.88 (0.79 to 0.99)
Trend 0.031 0.029
N=3192 N=3192
Patients with
diabetes
1.01 (0.90 to 1.13)† 0.259 3192 0.99 (0.92 to 1.06)† 0.683
Ordinal regression 0.99 (0.91 to 1.09)
1st quintile 0.25–0.8 Ref. 0.25–1.6 Ref.
2nd quintile 0.9–1.1 1.06 (0.80 to 1.40) 1.7–2.3 1.06 (0.81 to 1.38)
3rd quintile 1.2–1.4 0.88 (0.66 to 1.17) 2.4–3.2 1.10 (0.85 to 1.42)
4th quintile 1.5–1.8 1.03 (0.77 to 1.36) 3.3–5.0 1.02 (0.79 to 1.33)
5th quintile 1.9–14.5 1.08 (0.82 to 1.43) 5.1–99.7 1.00 (0.77 to 1.31)
Trend 0.620 0.942
*Using clinical record validated diagnosis of diabetes and self-reported use of medications, adjusted for age (1-year age bands), ethnicity,
gender, school level (categorical), household income (categorical), physical activity, alcohol consumption (categorical, none/<1drink/month,
<1 drink/week, few drinks/week, 1–3 drinks/day, >3 drinks/day, undetermined) and cigarette smoking (categorical, never, former, <10
cigarette/day, 12–20 cigarette/day, 20+ cigarette/day).
†OR for doubling PFAA concentration.
PFAA, perfluoroalkyl acids.
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presence of confounding at either level, but if the associ-
ation had been consistent at both the individual and dis-
trict levels, that would have been more convincing
evidence of the association being due to PFAAs.
The size of the associations observed has both strong
and weak aspects. The strong statistical signiﬁcance sug-
gests that chance is an unlikely explanation. However,
the ORs are only modestly different from one, 0.75 at
the most extreme, so that biases are a more plausible
explanation than they would be with more extreme
ratios. In conclusion, these data show an inverse associ-
ation between PFOA and PFOS exposure and self-
reported memory impairment, particularly in patients
without diabetes. This can be potentially explained by
the preventive anti-inﬂammatory effect exerted by a
PPAR agonist effect of these PFAAs, but confounding or
even reverse causation cannot be excluded as an alterna-
tive explanation.
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Range
(ng/ml)
OR (95% CI)* N=7097
restricted to those
aged 65+†
Range
(ng/ml)
OR (95% CI)*N=21024
any memory impairment‡
PFOS 0.95 (0.90 to 1.00) 0.96 (0.94 to 0.99)
Ordinal regression 0.98 (0.94 to 1.03)
1st quintile 0.25–15.3 Ref. 0.25–14.4 Ref.
2nd quintile 15.4–22.0 0.99 (0.83 to 1.20) 14.5–20.4 0.96 (0.88 to 1.05)
3rd quintile 22.1–28.9 0.95 (0.79 to 1.14) 20.5–27.1 0.90 (0.82 to 0.98)
4th quintile 29.0–4.0 0.97 (0.81 to 1.16) 27.2–37.2 0.94 (0.86 to 1.03)
5th quintile 40.1–759.2 0.84 (0.70 to 1.01) 37.3–759.2 0.93 (0.85 to 1.02)
Trend 0.079 0.121
PFOA 0.99 (0.97 to 1.03) 0.97 (0.96 to 0.99)
Ordinal regression 1.00 (0.97 to 1.03)
1st quintile 0.25–15.0 Ref. 0.25–14.0 Ref.
2nd quintile 15.1–29.6 0.91 (0.75 to 1.09) 14.1–27.0 0.90 (0.82 to 0.98)
3rd quintile 29.7–56.8 0.90 (0.75 to 1.08) 27.1–53.8 0.86 (0.79 to 0.94)
4th quintile 56.9–123.0 0.84 (0.70 to 1.01) 53.9–118.1 0.87 (0.79 to 0.95)
5th quintile 123.1–5994.8 0.99 (0.83 to 1.19) 118.3–22,412 0.85 (0.78 to 0.93)
Trend 0.680 <0.001
PFNA 0.95 (0.87 to 1.02) 0.98 (0.95 to 1.02)
Ordinal regression 0.99 (0.93 to 1.07)
1st quintile 0.25–0.8 Ref. 0.25–0.90 Ref.
2nd quintile 0.9–1.1 0.88 (0.73 to 1.06) 1.0–1.2 0.89 (0.82 to 0.97)
3rd quintile 1.2–1.4 0.81 (0.67 to 0.98) 1.3–1.4 0.94(0.85 to 1.04)
4th quintile 1.5–1.8 0.82 (0.68 to 0.99) 1.5–1.9 0.92 (0.85 to 1.01)
5th quintile 1.9–11.7 0.88 (0.73 to 1.07) 2.0–28.6 0.94 (0.86 to 1.03)
Trend 0.177 0.493
PFHxS 0.96 (0.91 to 1.01) 0.97 (0.94 to 0.99)
Ordinal regression 0.98 (0.93 to 1.02)
1st quintile 0.25–1.9 Ref. 0.25 to 1.7 Ref.
2nd quintile 2.0–2.8 0.98 (0.82 to 1.18) 1.8 to 2.6 0.98 (0.90 to 1.07)
3rd quintile 2.9–3.9 0.95 (0.79 to 1.15) 2.7 to 3.6 1.03 (0.94 to 1.13)
4th quintile 4.0–6.0 0.98 (0.82 to 1.17) 3.7 to 5.6 0.96 (0.87 to 1.04)
5th quintile 6.1–232.6 0.86 (0.71 to 1.03) 5.7 to 232.6 0.89 (0.81 to 0.97)
Trend 0.139 0.010
*Model 2 includes age (1-year age bands), ethnicity, gender, and school level (categorical), household income (categorical), physical activity,
alcohol consumption (categorical, none/<1drink/month, <1 drink/week, few drinks/week, 1–3 drinks/day, >3 drinks/day, undetermined) and
cigarette smoking (categorical, never, former, <10 cigarette/day, 12–20 cigarette/day, 20+ cigarette/day).
†Sensitivity analysis including participants aged 65 years or older only (N=7097).
‡Sensitivity analysis using a more restrictive definition of memory impairment (those reporting frequent episode of short-term memory loss
only, cases=1115).
PFAA, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanate; PFOS,
perfuorooctane sulfonate.
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